Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Candidate gene therapy for hemophilia gives promising results in canine studies

Oct. 5, 1998

Potent, long-acting TxA2 receptor antagonist enters Pfizer development pipeline

Oct. 1, 1998

YM-377 as a treatment for coronary occlusive diseases

Sep. 29, 1998

U.S. patent issues for Bio-Technology General's anticoagulant polypeptide

Sep. 28, 1998

Organon designs nonpeptide thrombin inhibitors mimicking D-Phe-Pro-Arg

Sep. 25, 1998

Controlled clinical trial demonstrates efficacy of cilostazol in intermittent claudication

Sep. 23, 1998

Neutralase preclinical data published; clinical trial still on hold

Sep. 22, 1998

Astra describes SAR leading to antithrombotic agent with novel mechanism of action

Sep. 18, 1998

Sanofi/BMS antiplatelet agent introduced in U.K.

Sep. 17, 1998

Organon discovers new pharmacophore providing potent, orally active thrombin inhibitors

Sep. 17, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.